Home LiteratureArticle Details
PMID: 17549249 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Adoptive T cell therapy for cancer in the clinic.

The Journal of clinical investigation ·Vol. 117 ·No. 6 ·2007-06-00 ·Pages 1466-76

June CH

Abstract

The transfusion of lymphocytes, referred to as adoptive T cell therapy, is being tested for the treatment of cancer and chronic infections. Adoptive T cell therapy has the potential to enhance antitumor immunity, augment vaccine efficacy, and limit graft-versus-host disease. This form of personalized medicine is now in various early- and late-stage clinical trials. These trials are currently testing strategies to infuse tumor-infiltrating lymphocytes, CTLs, Th cells, and Tregs. Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein.

MeSH Terms
Cancer Vaccines/therapeutic use Clinical Trials as Topic Combined Modality Therapy Genetic Engineering Humans Immunotherapy, Adoptive/methods Lymphocytes, Tumor-Infiltrating/immunology Neoplasms/immunology,therapy T-Lymphocytes/immunology T-Lymphocytes, Cytotoxic/immunology
Chemicals
Cancer Vaccines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
June Carl H
Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. [email protected]
References (131)
131 references, click to expand
  1. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
    J Clin Oncol. 1999 Jul;17(7):2044-9 PMID: 10561256
  2. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma.
    J Clin Oncol. 1999 Aug;17(8):2521-9 PMID: 10561318
  3. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
    Adv Immunol. 2000;74:181-273 PMID: 10605607
  4. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.
    Lancet. 2000 Sep 2;356(9232):802-7 PMID: 11022927
  5. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    J Immunol. 2000 Oct 15;165(8):4246-53 PMID: 11035058
  6. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    J Exp Med. 2000 Dec 4;192(11):1637-44 PMID: 11104805
  7. Functional expression of chimeric receptor genes in human T cells.
    J Immunol Methods. 2001 Feb 1;248(1-2):67-76 PMID: 11223069
  8. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Cancer Res. 2001 Mar 1;61(5):2031-7 PMID: 11280763
  9. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.
    Nature. 2001 Apr 26;410(6832):1107-11 PMID: 11323675
  10. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Cancer Res. 2001 May 1;61(9):3689-97 PMID: 11325840
  11. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  12. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential.
    Blood. 2001 Aug 1;98(3):597-603 PMID: 11468156
  13. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  14. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection.
    Nat Med. 2002 Jan;8(1):47-53 PMID: 11786906
  15. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
    Cancer Res. 2002 Feb 1;62(3):796-800 PMID: 11830535
  16. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.
    Cancer Res. 2002 Mar 1;62(5):1462-70 PMID: 11888921
  17. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.
    Clin Cancer Res. 2002 Jun;8(6):1767-71 PMID: 12060615
  18. T-cell-receptor gene therapy.
    Nat Rev Immunol. 2002 Jul;2(7):512-9 PMID: 12094225
  19. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma.
    Cancer Immunol Immunother. 2002 Nov;51(10):539-46 PMID: 12384805
  20. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    J Immunol. 2002 Nov 1;169(9):4811-21 PMID: 12391191
  21. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  22. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2.
    Hum Gene Ther. 2002 Nov 1;13(16):1971-80 PMID: 12427307
  23. Towards patient-specific tumor antigen selection for vaccination.
    Immunol Rev. 2002 Oct;188:164-76 PMID: 12445290
  24. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 PMID: 12427970
  25. Targeting tumours with genetically enhanced T lymphocytes.
    Nat Rev Cancer. 2003 Jan;3(1):35-45 PMID: 12509765
  26. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  27. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.
    Cancer Cell. 2003 May;3(5):431-7 PMID: 12781360
  28. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
    J Immunol. 2003 Jun 15;170(12):6338-47 PMID: 12794167
  29. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
    J Immunother. 2003 Jul-Aug;26(4):332-42 PMID: 12843795
  30. Suicide genes as safety switches in T lymphocytes.
    Cytotherapy. 2003;5(3):227-30 PMID: 12850790
  31. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Nat Med. 2003 Sep;9(9):1144-50 PMID: 12925844
  32. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
    Blood. 2003 Sep 15;102(6):2004-13 PMID: 12763934
  33. Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production.
    J Exp Med. 2003 Sep 15;198(6):947-55 PMID: 12963692
  34. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Science. 2003 Oct 17;302(5644):415-9 PMID: 14564000
  35. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.
    Cancer Res. 2003 Oct 15;63(20):6838-46 PMID: 14583481
  36. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model.
    Cancer Immunol Immunother. 2003 Dec;52(12):739-50 PMID: 12827306
  37. Focus on hepatocellular carcinoma.
    Cancer Cell. 2004 Mar;5(3):215-9 PMID: 15050913
  38. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.
    Blood. 2004 Jul 15;104(2):453-61 PMID: 15031211
  39. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells.
    Blood. 2004 Aug 1;104(3):895-903 PMID: 15090447
  40. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    J Exp Med. 2004 Sep 20;200(6):771-82 PMID: 15381730
  41. Effect of leukocytes on transplantability of human cancer.
    Cancer. 1966 Nov;19(11):1743-53 PMID: 5925282
  42. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.
    J Immunol. 1980 Oct;125(4):1487-93 PMID: 6967906
  43. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.
    J Exp Med. 1982 Apr 1;155(4):968-80 PMID: 6977616
  44. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease.
    Blood. 1986 Sep;68(3):770-3 PMID: 3527302
  45. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
    N Engl J Med. 1988 Jun 16;318(24):1557-63 PMID: 3259674
  46. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms.
    N Engl J Med. 1989 Mar 30;320(13):828-34 PMID: 2648143
  47. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    J Immunol. 1989 Jul 15;143(2):740-8 PMID: 2738408
  48. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
    J Immunol. 1990 Sep 1;145(5):1615-20 PMID: 1974569
  49. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
    J Immunol. 1991 Jul 15;147(2):729-37 PMID: 1830072
  50. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.
    Adv Immunol. 1991;49:281-355 PMID: 1853786
  51. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
    Science. 1991 Dec 13;254(5038):1643-7 PMID: 1840703
  52. High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy.
    J Immunother (1991). 1991 Dec;10(6):405-11 PMID: 1768674
  53. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
    Cancer Res. 1992 Feb 1;52(3):548-53 PMID: 1732041
  54. The use of ex vivo-activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study.
    Semin Urol. 1993 Feb;11(1):27-34 PMID: 8465126
  55. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 PMID: 8028037
  56. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    J Immunol. 1995 Jul 1;155(1):118-27 PMID: 7541409
  57. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.
    Blood. 1995 Aug 15;86(4):1261-8 PMID: 7632930
  58. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
    Science. 1995 Oct 20;270(5235):475-80 PMID: 7570001
  59. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
    J Immunol. 1996 Jan 1;156(1):238-45 PMID: 8598468
  60. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients.
    Nat Med. 1996 Feb;2(2):216-23 PMID: 8574968
  61. Cancer immunotherapy: breaking the barriers to harvest the crop.
    Nat Med. 2004 Sep;10(9):887-92 PMID: 15340404
  62. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  63. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Clin Cancer Res. 2004 Sep 1;10(17):5907-18 PMID: 15355924
  64. Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.
    Cancer Res. 2006 Jun 15;66(12):6387-94 PMID: 16778217
  65. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  66. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  67. Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.
    Blood. 1999 Nov 1;94(9):3222-33 PMID: 10556211
  68. Principles of adoptive T cell cancer therapy.
    J Clin Invest. 2007 May;117(5):1204-12 PMID: 17476350
  69. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.
    Blood. 2007 Jun 1;109(11):4698-707 PMID: 17327416
  70. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer.
    J Natl Cancer Inst. 1993 Apr 21;85(8):622-32 PMID: 8468720
  71. Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.
    Blood. 1996 Apr 1;87(7):2930-7 PMID: 8639913
  72. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Cancer. 1995 Sep 1;76(5):824-32 PMID: 8625186
  73. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma.
    Cancer. 1996 Jul 15;78(2):244-51 PMID: 8673999
  74. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    J Clin Oncol. 1997 Feb;15(2):796-807 PMID: 9053507
  75. Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene.
    J Immunol. 1997 Jun 1;158(11):5079-82 PMID: 9164920
  76. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
    Science. 1997 Jun 13;276(5319):1719-24 PMID: 9180086
  77. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
    Blood. 1997 Jun 15;89(12):4531-6 PMID: 9192777
  78. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.
    Immunol Rev. 1997 Jun;157:195-216 PMID: 9255631
  79. Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
    Immunol Rev. 1997 Jun;157:217-22 PMID: 9255632
  80. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
    J Immunol. 1997 Dec 15;159(12):5921-30 PMID: 9550389
  81. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
    J Clin Oncol. 1998 Aug;16(8):2752-60 PMID: 9704728
  82. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.
    Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42 PMID: 9724721
  83. Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model.
    J Immunol. 1998 Nov 15;161(10):5133-7 PMID: 9820481
  84. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
    Clin Cancer Res. 1999 Feb;5(2):461-9 PMID: 10037198
  85. Inducing autoimmune disease to treat cancer.
    Proc Natl Acad Sci U S A. 1999 May 11;96(10):5340-2 PMID: 10318881
  86. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth.
    Hum Gene Ther. 1999 Aug 10;10(12):1941-51 PMID: 10466628
  87. The makings of a tumor rejection antigen.
    Immunity. 1999 Sep;11(3):263-70 PMID: 10514004
  88. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer.
    J Exp Med. 1955 Aug 1;102(2):157-77 PMID: 13242741
  89. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.
    Blood. 2005 Jan 1;105(1):13-21 PMID: 15353480
  90. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.
    Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):419-24 PMID: 15623559
  91. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
    Trends Immunol. 2005 Feb;26(2):111-7 PMID: 15668127
  92. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  93. Augmentation of post transplant immunity: antigen encounter at the time of hematopoietic stem cell transplantation enhances antigen-specific donor T-cell responses in the post transplant repertoire.
    Bone Marrow Transplant. 2005 Apr;35(8):793-801 PMID: 15750607
  94. Immunotherapy and chemotherapy--a practical partnership.
    Nat Rev Cancer. 2005 May;5(5):397-405 PMID: 15864281
  95. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Bone Marrow Transplant. 2005 Aug;36(4):315-23 PMID: 15968284
  96. Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells.
    J Immunol. 2005 Oct 1;175(7):4797-805 PMID: 16177129
  97. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
    Cancer Res. 2005 Oct 15;65(20):9547-54 PMID: 16230420
  98. Selective activation of peripheral blood T cell subsets by endotoxin infusion in healthy human subjects corresponds to differential chemokine activation.
    J Immunol. 2005 Nov 1;175(9):6155-62 PMID: 16237112
  99. Silencing and variegation of gammaretrovirus and lentivirus vectors.
    Hum Gene Ther. 2005 Nov;16(11):1241-6 PMID: 16259557
  100. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.
    Nat Med. 2005 Nov;11(11):1238-43 PMID: 16227988
  101. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
    Nat Med. 2005 Nov;11(11):1230-7 PMID: 16227990
  102. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
    Cancer Res. 2005 Nov 15;65(22):10569-77 PMID: 16288050
  103. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  104. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  105. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Clin Cancer Res. 2006 Jan 15;12(2):569-76 PMID: 16428502
  106. Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.
    Biol Blood Marrow Transplant. 2006 Feb;12(2):226-34 PMID: 16443520
  107. Restoring function in exhausted CD8 T cells during chronic viral infection.
    Nature. 2006 Feb 9;439(7077):682-7 PMID: 16382236
  108. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation.
    Blood. 2006 Mar 15;107(6):2294-302 PMID: 16282341
  109. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
    J Clin Oncol. 2006 May 1;24(13):e20-2 PMID: 16648493
  110. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration.
    Nat Biotechnol. 2006 Jun;24(6):687-96 PMID: 16732270
  111. The consensus coding sequences of human breast and colorectal cancers.
    Science. 2006 Oct 13;314(5797):268-74 PMID: 16959974
  112. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
    Leukemia. 2006 Oct;20(10):1819-28 PMID: 16932339
  113. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 PMID: 17062687
  114. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    J Clin Oncol. 2006 Nov 1;24(31):5060-9 PMID: 17075125
  115. Gene transfer in humans using a conditionally replicating lentiviral vector.
    Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7 PMID: 17090675
  116. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
    J Exp Med. 2006 Nov 27;203(12):2691-702 PMID: 17101732
  117. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Cancer Res. 2006 Dec 1;66(23):11447-54 PMID: 17145892
  118. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor.
    Cryobiology. 2006 Dec;53(3):360-6 PMID: 16973145
  119. Calreticulin exposure dictates the immunogenicity of cancer cell death.
    Nat Med. 2007 Jan;13(1):54-61 PMID: 17187072
  120. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
    J Exp Med. 2007 Jan 22;204(1):49-55 PMID: 17210731
  121. To ablate or not to ablate? HSCs in the T cell driver's seat.
    J Clin Invest. 2007 Feb;117(2):306-10 PMID: 17273553
  122. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
    J Clin Invest. 2007 Feb;117(2):492-501 PMID: 17273561
  123. Unique human tumor antigens: immunobiology and use in clinical trials.
    J Immunol. 2007 Feb 15;178(4):1975-9 PMID: 17277099
  124. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Mol Ther. 2007 Apr;15(4):825-33 PMID: 17299405
  125. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
    J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 PMID: 10655437
  126. Phase II study of combined immunotherapy, chemotherapy, and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer.
    J Immunother. 2000 Jan;23(1):161-7 PMID: 10687149
  127. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
    J Immunol. 2000 May 1;164(9):4941-54 PMID: 10779805
  128. Control of homeostasis of CD8+ memory T cells by opposing cytokines.
    Science. 2000 Apr 28;288(5466):675-8 PMID: 10784451
  129. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.
    Blood. 2000 Aug 1;96(3):785-93 PMID: 10910888
  130. The epidemiology of acquired immunodeficiency syndrome malignancies.
    Semin Oncol. 2000 Aug;27(4):390-401 PMID: 10950365
  131. Eradication of established tumors by CD8+ T cell adoptive immunotherapy.
    Immunity. 2000 Aug;13(2):265-76 PMID: 10981969
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI32446
Email
[email protected]
Published
2007-06-00
Pages
1466-76
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1878537
Subset
IM
Grants
NCI NIH HHS · R01 CA105216 · United States
NCI NIH HHS · 1R01CA104679 · United States
NCI NIH HHS · R01 CA105216-03 · United States
NCI NIH HHS · 5P50CA083638 · United States
NCI NIH HHS · P50 CA083638 · United States
NCI NIH HHS · 5R01CA105216 · United States
External Links
PubMed source DOI: 10.1172/JCI32446 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2